News for Zymeworks Inc. (ZYME)

Zymeworks (ZYME) has achieved a significant milestone as China's National Medical Products Administration granted conditional approval for zanidatamab. This app

Zymeworks (ZYME) receives NMPA approval in China for zanidatamab, a first-of-its-kind bispecific antibody for HER2+ biliary tract cancer. The approval t

Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the res

On May 16, 2025, Redmile Group, LLC (Trades, Portfolio) executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Ata

**media[634760]**

Zymeworks Inc. (ZYME) announced its participation in three major investor conferences in June 2025. The company will hold one-on-one meetings and firesi

VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME), a clinical-stage biotechnology company developing a diverse pipeline of

Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways cr

Zymeworks, trading under the ticker ZYME, has unveiled promising preclinical findings for its innovative bispecific molecule, ZW1528, which targets respiratory

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zymeworks Inc (ZY

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NZYME.OQ - Zymeworks IncQ1 2025 Zymeworks Inc Earnings CallMay 08, 2025 / 08:30PM GMT =========

Zymeworks Inc. (NASDAQ:ZYME) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsShrinal Inamdar - Senior Director, Investor...

The following slide deck was published by Zymeworks Inc.

Zymeworks (ZYME) reported first-quarter revenue of $27.11 million, significantly exceeding the anticipated $20.65 million. This achievement highlights the compa

Six posters presented at the American Association for Cancer Research (AACR) annual meetingAppointment of Dr. Sabeen Mekan as Senior Vice President, Clinical De

Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Revenue: $27.1 million for Q1 2025, surpassing the estimated $20.65 million and significantly up from $10.0 million in Q1 2024.Net Loss: Reduced to $22.6 milli

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity i

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME), a clinical-stage biotechnology company developing a diverse pipeline o